Zhi Tong Cai Jing·2026-01-15 00:52Group 1 - The core focus of WuXi AppTec is on its GLP-1 drug pipeline, with the company currently supporting 24 GLP-1 drugs, including both small molecules and peptides [1][2] - Out of the 24 GLP-1 drugs, 15 have entered phase II and III clinical trials, positioning the company to potentially capture approximately 25% of the global GLP-1 market share [1] Group 2 - The demand for GLP-1 drugs has seen exponential growth, revealing deficiencies in the core pharmaceutical supply chain, which has been historically rare [2] - WuXi AppTec has proactively built its production capacity, recently completing the construction of a 100,000-liter solid-phase synthesis reactor to enhance large-scale production capabilities [2] - As the accessibility of GLP-1 drugs improves, the treatment landscape for obesity and related metabolic diseases is expected to undergo significant transformation, indicating the beginning of a "therapeutic revolution" [2]